<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Strength of Evidence</title>

<script src="site_libs/header-attrs-2.17/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="site_libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="site_libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="site_libs/kePrint-0.0.1/kePrint.js"></script>
<link href="site_libs/lightable-0.0.1/lightable.css" rel="stylesheet" />

<link rel="icon" href="https://github.com/workflowr/workflowr-assets/raw/main/img/reproducible.png">
<!-- Add a small amount of space between sections. -->
<style type="text/css">
div.section {
  padding-top: 12px;
}
</style>



<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">NMB</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="soe.html">Strength of Evidence</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Technical
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq1.html">Results</a>
    </li>
    <li>
      <a href="summary_tech.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Diagnostic
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq2.html">Results</a>
    </li>
    <li>
      <a href="summary_kq2.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Outcomes
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq3.html">Results</a>
    </li>
    <li>
      <a href="tofr_confirm.html">TOFR Confirmed Before Extubation</a>
    </li>
    <li>
      <a href="summary_kq3.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Reversal
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="reversal.html">Sugammadex vs. Neostigmine</a>
    </li>
    <li>
      <a href="summary_rev.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
    <li>
      <a href="reversal_cis.html">Cisatracurium</a>
    </li>
  </ul>
</li>
<li>
  <a href="evidence_tables.html">Evidence Tables</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Appendices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="prisma.html">PRISMA</a>
    </li>
    <li>
      <a href="outcome_importance.html">Outcome Importance</a>
    </li>
  </ul>
</li>
<li>
  <a href="about.html">About</a>
</li>
<li>
  <a href="license.html">License</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Strength of Evidence</h1>
<h4 class="date">18 October, 2022 (18:31)</h4>

</div>


<style type="text/css">
  body{
  font-size: 9.5pt;
  font-family: Source Sans Pro;
}

.list-group-item.active, .list-group-item.active:hover, .list-group-item.active:focus {
  color: #090909;
  background-color: #0909093d;
}

.lightable-classic.lightable-hover tbody tr:hover {
    background-color: #c5d4e4;
}
.btn-xs, .btn-group-xs>.btn { 
display: none; 
}

.btn-default {
display: none !important; 
}

@font-face {
    font-family: "GRADE-quality";
    src: url();
    src: url('https://gradepro.org/fonts/GRADE-quality.eot');
    src: url('https://gradepro.org/fonts/GRADE-quality.eot?#iefix')
        format('embedded-opentype'),
      url('https://gradepro.org/fonts/GRADE-quality.woff') format('woff'),
      url('https://gradepro.org/fonts/GRADE-quality.ttf') format('truetype'),
      url('https://gradepro.org/fonts/GRADE-quality.svg#GRADE-quality')
        format('svg');
    font-weight: normal;
    font-style: normal;
}

.quality-sign {
      font-family: 'GRADE-quality', Cambria, Helvetica, Arial;
      font-size: 10px;
      vertical-align: text-top;
    }

span { font-size: 3em;}

span b { font-size: 60%; font-weight: normal }


</style>
<p><font size = 4> Ratings for important outcomes according to study
design.</font></p>
<div id="nmm-technical-performance" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Technical Performance</strong><a
href="#nmm-technical-performance" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings" class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 1. Strength of evidence for outcomes relevant
to neuromuscular monitor technical performance. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACCF/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="6">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Fully Paired</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Corrugator Supercilii</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR<br>≥ 0.9 or 1.0
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(140)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 fully paired studies and 1 RCT reported shorter times to TOFR
≥0.9 or ≥1.0 when measured at the corrigator supercilii vs. adductor
pollicis. This finding was consistent in patients recovering
spontaneously or administered sugammadex, and in young adults and
elderly (≥70 yrs). One small fully paired study did not detect a
difference.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br>≥ 0.8 or 0.9
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(46)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two fully paired studies (spontaneous recovery or neostigmine) reported
shorter times to TOFR ≥0.8 or ≥0.9 when measured at the obicularis oculi
vs. adductor pollicis.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Masseter</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(10)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study (n=10) did not detect a difference in time to
TOFR ≥0.9 when measured at the masseter vs. adductor pollicis in
patients recovering spontaneously.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Flexor Hallucis Brevis</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(52)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported shorter times to TOFR ≥0.9 when measured
at the flexor hallucis brevis vs. adductor poliicis in patients
recovering spontaneously. A difference was not detected in patients
administered neostigmine.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Flexor Hallucis Brevis vs. First Dorsal Interosseous</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(29)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported shorter time to TOFR ≥0.9 when measured
at the flexor hallucis brevis vs. first dorsal interosseous among
patients recovering spontaneously.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Normalization vs. No Normalization</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(122)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported more frequent RNMB (TOFR &lt;1.0) when
using normalized measures vs. non-normalized measures. A difference was
not detected in severe RNMB (TOFR &lt;0.7).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Prospective Cohort</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(150)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One prospective cohort study reported more freqent RNMB when obicularis
oculi is monitored vs. adductor policis, OR 5.5 (95% CI, 2.1-14.5).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; TOFR: train of four
ratio; OR: odds ratio.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 2. GRADE domains for strength of evidence
rating for outcomes relevant to neuromuscular monitor technical
performance. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="6">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Fully Paired</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Corrugator Supercilii</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR<br>≥ 0.9 or 1.0
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired (3) and RCT (1)
</td>
<td style="text-align:left;width: 8em; ">
4 (140)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br>≥ 0.8 or 0.9
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired
</td>
<td style="text-align:left;width: 8em; ">
2 (46)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>3</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Masseter</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired
</td>
<td style="text-align:left;width: 8em; ">
1 (10)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Flexor Hallucis Brevis</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired
</td>
<td style="text-align:left;width: 8em; ">
1 (52)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Flexor Hallucis Brevis vs. First Dorsal Interosseous</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br>≥0.9
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired
</td>
<td style="text-align:left;width: 8em; ">
1 (29)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>8</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Normalization vs. No Normalization</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB
</td>
<td style="text-align:left;width: 8em; ">
Fully Paired
</td>
<td style="text-align:left;width: 8em; ">
1 (122)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Prospective Cohort</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicis vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB
</td>
<td style="text-align:left;width: 8em; ">
Cohort
</td>
<td style="text-align:left;width: 8em; ">
1 (150)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RCT: randomized controlled trial; NRSI: nonrandomized study
of interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Methodological heterogeneity: spontaneous/sugammadex; TOFR
threshold.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Overlapping distributions in one of the two studies.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Methodological heterogeneity: spontaneous/neostigmine; TOFR
threshold.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Estimate has large standard deviation; small sample size
(n=10).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> 13% excluded from analysis due to missing data and protocol
deviation.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Estimates have large standard deviations.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Estimate has large standard deviation.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Intermediate outcome.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Estimate has wide confidence interval.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
<p><br/></p>
</div>
</div>
<div id="nmm-outcomes" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Outcomes</strong><a
href="#nmm-outcomes" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings-1"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-1" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 3. Strength of evidence for outcomes following
neuromuscular monitoring (evidence obtained from RCTs unless noted).
</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACCF/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="2">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual NMB <br>TOFR &lt;0.7
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(188)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Three RCTs reported lower incidence of RNMB in patients with qualitative
vs. clinical assessement — pooled RR 0.38 (95% CI, 0.27-0.54);
I<sup>2</sup> = 0%.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig1">Figure 1</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(268)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Three of 4 RCTs reported lower mean TOFR at extubation or in the PACU
when patients are assessed clinically vs. qualitatively. One RCT did not
detect a difference.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(232)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Three RCTs reported lower incidence of RNMB in patients with
quantitative monitoring vs. clinical assessement — pooled RR 0.18 (95%
CI, 0.06-0.50) ; I<sup>2</sup> = 0%.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig2">Figure 2</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual NMB <br>TOFR &lt;0.9
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(329)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two RCTs reported lower incidence of RNMB in patients with quantitative
monitoring vs. qualitative assessment — pooled RR 0.24 (95% CI,
0.13-0.43) ; I<sup>2</sup> = 18%.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig3">Figure 3</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:center;width: 5em; ">
11 <br>(1230)
</td>
<td style="text-align:left;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Network meta-analysis of 8 RCTs, 1 quasi-experimental studies, and 1
retrospective cohort showed lower incidence of RNMB in patients
monitored quantitatively vs. assessed qualitatively vs. assessed
clinically. RR 0.27 (95% CI, 0.15-0.47) for quantitative
vs. qualitative; RR 0.06 quantitative vs. clinical (95% CI, 0.03-0.12);
RR 0.39 for qualitative vs. clinical (95% CI, 0.28-0.53).
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab5">Table 5</a><br> <a
href="kq3.html#kq3Fig5">Figure 5</a>
</td>
</tr>
<tr grouplength="3">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative or Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(262)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 RCTs reported lower mean TOFR at extubation or in the PACU when
patients are assessed clinically or qualitatively vs. quantitatively
monitored. One RCT did not detect a difference.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(192)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One quasi-experimental study reported lower mean TOFR in the PACU for
patients assessed clinically or qualitatively vs. quantitatively
monitored.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(419)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 RCTs reported higher incidence of hypoxia in patients assessed
clinically or qualitatively vs. quantitatively monitored. One RCT
reported no events.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary Complications
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(8678)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One study did not detect a difference in pulmonary complications in
patients quantitatively monitored vs. assessed qualitatively OR 1.07
(95% CI, 0.90-1.29). One before/after study reported fewer pulmonary
complications with the introduction of quantitaive monitors RR 0.25 (95%
CI, 0.17-0.38).
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr grouplength="11">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Any monitoring vs. none</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary Complications
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(17150)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One prospective cohort study reported more pulmonary complications in
patients monitored quantitatively vs. no monitoring. OR 1.31 (95% CI,
1.15-1.49).
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(112)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two RCTs did not detect a difference in mean TOFR at extubation/PACU in
patients assessed clinically vs. quantitatively monitoted.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(561)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Five RCTs reported lower incidence of RNMB in patients with quantitative
monitoring vs. clinical or qualitative assessment.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(150)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One RCT reported lower mean TOFR in the PACU in patients assessed
qualitatively compared with quantitative monitoring, p=0.004
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(192)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One quasi-experimental study reported lower mean TOFR in the PACU in
patients assessed qualitatively compared with quantitative monitoring,
p=0.008
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Reintubation
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(240)
</td>
<td style="text-align:left;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two RCTs comparing clinical assessment and quantitative monitoring
reported no reintubations in any arm.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Reintubation
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(155)
</td>
<td style="text-align:left;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One prospective cohort study comparing clinical assessment and
quantitative monitoring reported no reintubations in any arm.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(179)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One RCT reported higher hypoxia (&lt;90% O2) in patients assessed
qualiltatively compared with quantitative monitoring.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(240)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One RCT reported higher hypoxia (≥93% O2) in patients assessed
qualiltatively compared with quantitative monitoring and one RCT
reported no hypoxia in either arm.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Bronchospasm
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(72)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One RCT reported a single case of bronchospasm among patients monitored
quantitatively; none occurred in those clinically assessed.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pneumonia
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(155)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One prospective cohort reported 2 cases of pneumonia among patients
assessed clinically and none in the group monitored quantitatively.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; TOFR: train of four
ratio; RR: risk ratio.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Not rated as obtained from network meta-analysis agnostic
of study design. However, consistency of effects with that from the
randomized designs alone could argue for rating up the strength of
evidence.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-1" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-1"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 4. GRADE domains for strength of evidence
ratings relevant to outcomes with neuromuscular monitoring. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="2">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual NMB <br>TOFR &lt;0.7
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (188)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>3</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (268)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (232)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>8</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual NMB <br>TOFR &lt;0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (329)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>12</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:left;width: 4em; ">
8 RCTs, 2 quasi-experimental, and 1 retrospective cohort
</td>
<td style="text-align:left;width: 10em; ">
11 (1230)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>13</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>14</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>15</sup>
</td>
</tr>
<tr grouplength="3">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative or Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (262)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>16</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>17</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
Quasi-experimental
</td>
<td style="text-align:left;width: 10em; ">
1 (192)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (419)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>18</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>19</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary Complications
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
2 (8678)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="11">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Any monitoring vs. none</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary Complications
</td>
<td style="text-align:left;width: 4em; ">
Prospective Cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (17150)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (112)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>21</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual NMB <br>TOFR &lt;0.7 to 0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (561)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>8</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (150)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
Quasi-experimental
</td>
<td style="text-align:left;width: 10em; ">
1 (192)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Reintubation
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (240)
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Reintubation
</td>
<td style="text-align:left;width: 4em; ">
Prospective Cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (155)
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
not rated
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (179)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (240)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>22</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>23</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Bronchospasm
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (72)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pneumonia
</td>
<td style="text-align:left;width: 4em; ">
Prospective Cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (155)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Intermediate outcome; sugammadex not used in any trial.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Sufficient events given effect size and control incidence.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Large effect, but wide prediction interval; too few studies
to assess potential publication bias.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Three of 4 RCTs report lower mean TOFR in patients
monitored clinically vs. qualitatively. One did not detect a difference.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Intermediate outcome; sugammadex not used.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> Estimates have wide confidence intervals.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Wide confidence interval but does does not cross the
decision treatment threshold.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Large effect, but wide confidence and prediction intervals;
too few studies to assess potential publication bias.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Intermediate outcome.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>11</sup> Limited number of events.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>12</sup> Large effect but based on 2 trials from same
investigators; too few studies to assess potential publication bias.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>13</sup> Low heterogeneity (<em>I<sup>2</sup></em> = 25%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>14</sup> Intermediate outcome; sugammadex used in one observational
study.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>15</sup> Large effects but methodological heterogeneity related to
different study designs and TOFR thresholds.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>16</sup> Two of 3 RCTs report lower mean TOFR in patients monitored
either clinically or qualitatively vs. quantitatively. One did not
detect a difference.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>17</sup> Methodological heterogeneity.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>18</sup> Limited number of events.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>19</sup> Methodological heterogeneity: different thresholds for
hypoxia.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>20</sup> Deviations from intended interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>21</sup> Methodological heterogeneity (one measured at extubation,
one in PACU).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>22</sup> One study reports higher incidence with clinical
monitoring; one reported none in either arm.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>23</sup> One study defined hypoxia as ≤93% O2; other study did not
provide threshold.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
</div>
</div>
<div id="nmm-confirm-tofr-before-extubation"
class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Confirm TOFR Before
Extubation</strong><a href="#nmm-confirm-tofr-before-extubation"
class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings-2"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-2" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 5. Strength of evidence for TOFR confirmation
prior to extubation.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACCF/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>      Sugammadex</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual neuromuscular blockade
</td>
<td style="text-align:center;width: 5em; ">
21 <br>(1556)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
A lower incidence of residual neuromuscular blockade (TOFR &lt;0.9) was
observed in study arms when TOFR ≥0.9 was confirmed prior to extubation.
The estimated incidence of residual neuromuscular blockade with
confirmation was 0.5 per 100 (95% CI, 0.0 to 6.0); without confirmation
2.2 per 100 (95% CI, 0.5 to 9.0).
</td>
<td style="text-align:left;width: 7em; ">
<a href="tofr_confirm.html#confTab1">Table 1</a><br> <a
href="tofr_confirm.html#confFig1">Figure 1</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>      Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Residual neuromuscular blockade
</td>
<td style="text-align:center;width: 5em; ">
16 <br>(1979)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
A lower incidence of residual neuromuscular blockade (TOFR &lt;0.9) was
observed in study arms when TOFR ≥0.9 was confirmed prior to extubation.
The estimated incidence of residual neuromuscular blockade with
confirmation was 5.3 per 100 (95% CI, 2.5 to 10.7); without confirmation
39.8 per 100 (95% CI, 23.5 to 58.8).
</td>
<td style="text-align:left;width: 7em; ">
<a href="tofr_confirm.html#confTab2">Table 2</a><br> <a
href="tofr_confirm.html#confFig1">Figure 1</a>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-2" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-2"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 6. GRADE domains for strength of evidence
ratings for TOFR confirmation prior to extubation.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual neuromuscular blockade
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
21 (1556)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Residual neuromuscular blockade
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
16 (1979)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
rate up<sup>2</sup>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Similar confidence intervals for the confirmation or not.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Strong effect.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
</div>
</div>
<div id="reversal" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>Reversal</strong><a href="#reversal"
class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p><a id="soeReversal"></a></p>
<p><br/></p>
<div id="strength-of-evidence-ratings-3"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-3" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 7. Strength of evidence for reversal
outcomes.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACCF/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt;0.9
</td>
<td style="text-align:center;width: 5em; ">
8 <br>(1451)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
8 RCTs reported less RNMB (TOFR &lt;0.9) among patients reversed with
sugammadex vs. neostigmine. <br> RR 0.18 (95% CI, 0.07 to 0.42;
I<sup>2</sup> = 65%) <br> RD -21.6% (95% CI, -33.8% to -9.4%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab4">Table 4</a><br> <a
href="reversal.html#kq4Fig2">Figure 2</a><br> <a
href="reversal.html#kq4Fig3">Figure 3</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt;0.7
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(591)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 RCTs reported less RNMB (TOFR &lt;0.7) among patients reversed with
sugammadex vs. neostigmine.<br> RR 0.18 (95% CI, 0.08 to 0.39;
I<sup>2</sup> = 14%) <br> RD -14.4% (95% CI, -22.5% to -6.3%).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab4">Table 4</a><br> <a
href="reversal.html#kq4Fig3">Figure 3</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥0.9 from deep NMB
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(308)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 RCTs reported shorter times to TOFR ≥0.9 when reversed with sugammadex
vs. neostigmine from deep NMB. Pooled MD -33.6 (95% CI, -59.3 to -7.9)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab8">Table 8</a><br> <a
href="reversal.html#kq4Fig4">Figure 4</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥0.9 from moderate NMB
</td>
<td style="text-align:center;width: 5em; ">
17 <br>(1114)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
15 RCTs reported shorter times to TOFR ≥0.9 when reversed with
sugammadex vs. neostigmine from moderate NMB. Pooled MD -10.0 (95% CI,
-12.7 to -7.2)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab8">Table 8</a><br> <a
href="reversal.html#kq4Fig5">Figure 5</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥0.9 from shallow NMB
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(153)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
5 RCTs reported shorter times to TOFR ≥0.9 when reversed with sugammadex
vs. neostigmine from shallow NMB. Pooled MD -4.0 (95% CI, -6.2 to -1.7).
(Task force suggested a clinically meaningful threshold of 5 minutes or
potentially less.)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab8">Table 8</a><br> <a
href="reversal.html#kq4Fig6">Figure 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥0.9 from minimal NMB
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(17)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
1 RCT reported shorter times to TOFR ≥0.9 by 1.4 minutes when reversed
with sugammadex vs. neostigmine from minimal NMB.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab8">Table 8</a><br> <a
href="reversal.html#kq4Fig7">Figure 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Reparalysis
</td>
<td style="text-align:center;width: 5em; ">
13 <br>(705)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
11 RCTs reported no reparalysis events with sugammadex and neostigmine.
1 RCT reported fewer events with sugammadex and 1 RCT reported fewer
events with neostigmine.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab27">Table 27</a><br> <a
href="reversal.html#kq4Fig26">Figure 26</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Anaphylaxis
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(268)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
2 RCTs reported no anaphylaxis events for sugammadex or neostigmine.
Pooled RR 1.03 (95% CI, 0.73 to 1.46 I<sup>2</sup> = 10%, tau &lt;0.1).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab11">Table 11</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Anaphylaxis
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(114243)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
2 studies reported no anaphylaxis with sugammadex, 3 observational
studies reported incidence range between 0.01 - 0.04. Anaphylaxis was
not reported with neostigmine (3 studies, 26051 patients); in patients
receiving sugammadex (5 studies, 88192 patients) the pooled incidence
was 1.6 per 10,000 (95% CI, 0.9 to 2.7), tau = 0.8.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab11">Table 11</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Bradycardia<br>(neostigmine/glycopyrrolate)
</td>
<td style="text-align:center;width: 5em; ">
6 <br>(663)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Pooled results from 6 trials did not detect a difference in bradycardia
when glycopyrrolate was administered with neostigmine, RD -5.0% (95% CI,
-11.7% to 1.7%).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Bradycardia<br>(neostigmine/atropine)
</td>
<td style="text-align:center;width: 5em; ">
8 <br>(689)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Pooled results from 8 trials was consistent with higher incidence of
bradycardia when atropine was administered with neostigmine -5.0% (95%
CI, -11.7% to 1.7%).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Tachycardia<br>(neostigmine/glycopyrrolate)
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(314)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Pooled results from 3 trials did not detect a difference in tachycardia
when glycopyrrolate was administered with neostigmine, RD -6.7% (95% CI,
-14.5% to 1.0%).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Tachycardia<br>(neostigmine/atropine)
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(74)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Results from a single trial did not suggest a difference in tachycardia
when atropine was administered with neostigmine-10.8% (95% CI, -23.0% to
1.4%)
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Arrhythmia
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(374)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
In 5 RCTs, only 2 arrhythmic events reported (1 for sugammadex and 1 for
neostigmine). RD -1.0% (95% CI, -3.8% to 1.9%).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab14">Table 14</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
PONV
</td>
<td style="text-align:center;width: 5em; ">
16 <br>(1536)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Network meta-analysis estimate from 14 studies showed slight improvement
in PONV with sugammadex versus neostigmine RR 0.77 (95% CI, 0.61 to
0.97). An improvement comparing sugammadex with placebo/spontaneous
recovery, RR 0.70 (95% CI, 0.36 to 1.38). A difference was not detected
between neostigmine and placebo/spontaneous recovery, RR 0.91 (95% CI,
0.47 to 1.74). In CINeMA framework, no concerns related to incoherence.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab15">Table 15</a><br> <a
href="reversal.html#kq4Fig13">Figure 13</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Nausea
</td>
<td style="text-align:center;width: 5em; ">
26 <br>(2818)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Network meta-analysis did not show improvement in nausea with sugammadex
versus neostigmine or placebo/spontaneous recovery RR 0.94 (95% CI, 0.78
to 1.12) and RR 0.90 (95% CI, 0.51 to 1.59) respectively. A difference
was not detected between neostigmine and placebo/spontaneous RR 1.05
(95% CI, 0.67 to 1.65). In CINeMA framework, no concerns related to
incoherence.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab17">Table 17</a><br> <a
href="reversal.html#kq4Fig16">Figure 16</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Vomiting
</td>
<td style="text-align:center;width: 5em; ">
19 <br>(1959)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Network meta-analysis estimate showed slight improvement in vomiting
with sugammadex versus neostigmine or placebo/spontaneous RR 0.84 (95%
CI, 0.60 to 1.18) and RR 0.99 (95% CI, 0.30 to 3.25) respectively.
Neostigmine had fewer vomiting events compared to placebo/spontaneous RR
0.84 (95% CI, 0.48 to 1.49). In CINeMA framework, no concerns related to
incoherence.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab19">Table 19</a><br> <a
href="reversal.html#kq4Fig19">Figure 19</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia <br>(&lt;90%)
</td>
<td style="text-align:center;width: 5em; ">
6 <br>(670)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
3 RCTs reported fewer hypoxia (SpO2 &lt;90%) with sugammadex, 1 RCT
reported no hypoxic events, and 2 RCTs reported fewer hypoxic events
with neostigmine. RD -6.0 (95% CI, -18.2 to 6.2).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab21">Table 21</a><br> <a
href="reversal.html#kq4Fig21">Figure 21</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia <br> (90% to &lt;95%)
</td>
<td style="text-align:center;width: 5em; ">
7 <br>(792)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
2 RCTs reported fewer hypoxia (SpO2 91% to 95%) with sugammadex, 1 RCT
reported no hypoxic events, and 4 RCTs reported fewer hypoxic events
with neostigmine. Pooled RR 1.6 (95% CI, -3.6 to 6.8).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab21">Table 21</a><br> <a
href="reversal.html#kq4Fig21">Figure 21</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:center;width: 5em; ">
6 <br>(607)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
3 RCTs reported fewer pulmonary complications with sugammadex, 1 RCT
reported no events, and 2 RCTs reported fewer events with neostigmine.
Pooled OR 0.73 (95% CI, 0.51 to 1.03).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab22">Table 22</a><br> <a
href="reversal.html#kq4Fig22">Figure 22</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:center;width: 5em; ">
7 <br>(67787)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 studies reported fewer pulmonary complications with sugammadex, 1
study reported no events, and 3 studies reported fewer events with
neostigmine. Pooled OR 0.71 (95% CI, 0.56 to 0.90).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab22">Table 22</a><br> <a
href="reversal.html#kq4Fig22">Figure 22</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pneumonia
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(735)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
3 RCTs reported fewer pneumonia events with sugammadex, 1 RCT reported
more, and 1 reported same number of events as compared to neostigmine.
Pooled OR 0.49 (95% CI, 0.20 to 1.23).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab23">Table 23</a><br> <a
href="reversal.html#kq4Fig23">Figure 23</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pneumonia
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(57070)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 nonrandomized studies reported fewer pneumonia events with sugammadex
as compared to neostigmine. Pooled OR 0.59 (95% CI, 0.38 to 0.93).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab23">Table 23</a><br> <a
href="reversal.html#kq4Fig23">Figure 23</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postoperative reintubation
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(425)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
5 RCTs reported no postoperative reintubation with sugammadex and one
RCT reported 1 case with neostigmine. <br> Pooled RD -0.22% (95% CI,
-2.1% to 1.6%).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab26">Table 26</a><br> <a
href="reversal.html#kq4Fig25">Figure 25</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postoperative reintubation
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(18736)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 studies reported rates of postoperative reintubation with sugammadex
or neostigmine. <br> Pooled RD -1.7% (95% CI, -4.1% to 0.64%).
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab26">Table 26</a><br> <a
href="reversal.html#kq4Fig25">Figure 25</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Respiratory failure
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(100)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
1 RCT reported no occurence of respiratory failure in sugammadex or
neostigmine.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab24">Table 24</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Respiratory failure
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(47451)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
2 studies reported fewer occurence of respiratory failure with
sugammadex vs. neostigmine, 1 study reported no events, and 1 study
reported equivocal event rates.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#kq4Tab24">Table 24</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Cisatracurium and Atracurium</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥0.9 from moderate to minimal neuromuscular blockade
</td>
<td style="text-align:center;width: 5em; ">
6 <br>(126)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
5 studies reported median times between 3.8 and 16.5 minutes to TOFR
≥0.9 from moderate to minimal depths of neuromuscular blockade. One
study reported a mean of 10.3 (SD 1.3) minutes from moderate
neuromuscular blockade. Neostigmine dose ranged from 0.30 to 0.70 μg/kg.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; RR: risk ratio; RD:
risk difference; OR: odds ratio; MD: mean difference; RCT: randomized
controlled trial; NRSI: nonrandomized study of interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-3" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-3"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 8. GRADE domains for strength of evidence
ratings for reversal outcomes comparing sugammadex with neostigmine.
</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt;0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
8 (1451)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>3</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt;0.7
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (591)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>6</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥0.9 from deep NMB
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (308)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥0.9 from moderate NMB
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
17 (1114)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>8</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥0.9 from shallow NMB
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (153)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥0.9 from minimal NMB
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (17)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>11</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Reparalysis
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
13 (705)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>13</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Anaphylaxis
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (268)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>14</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Anaphylaxis
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
5 (114243)
</td>
<td style="text-align:left;width: 8em; ">
</td>
<td style="text-align:left;width: 8em; ">
</td>
<td style="text-align:left;width: 8em; ">
</td>
<td style="text-align:left;width: 8em; ">
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Bradycardia<br>(neostigmine/glycopyrrolate)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
6 (663)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>16</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Bradycardia<br>(neostigmine/atropine)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
8 (689)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>17</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Tachycardia<br>(neostigmine/glycopyrrolate)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (314)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>18</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Tachycardia<br>(neostigmine/atropine)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (74)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Arrhythmia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (374)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>19</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
PONV
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
16 (1536)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>21</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Nausea
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
26 (2818)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>22</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>21</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Vomiting
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
19 (1959)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>22</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia <br>(&lt;90%)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
6 (670)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>23</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>24</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia <br> (90% to &lt;95%)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
7 (792)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>25</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>26</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
6 (607)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>27</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>28</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
7 (67787)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>27</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>28</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pneumonia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (735)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>29</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pneumonia
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
4 (57070)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>30</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postoperative reintubation
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (425)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>31</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postoperative reintubation
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
4 (18736)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>32</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>33</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>34</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Respiratory failure
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (100)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>35</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Respiratory failure
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
4 (47451)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>36</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Cisatracurium and Atracurium</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥0.9 from moderate to minimal neuromuscular blockade
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
6 (126)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>37</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RCT: randomized controlled trial; Obs: observational
(nonrandomized).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Wide prediction interval (I<sup>2</sup> = 65% for pooled
RR).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Wide confidence interval, but upper bound (0.42) would not
alter decision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Methodological heterogeneity, but 3 trials did not report
depth of block. Large effect, not rated up owing to consideration of
precision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Wide 95% prediction interval (0.02–1.48).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Wide confidence interval, but upper bound (0.39) would not
alter decision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> Methodological heterogeneity, but 2 trials did not report
depth of block. Large effect, not rated up owing to consideration of
precision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Considerable heterogeneity (I<sup>2</sup> ≥ 96%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Considerable heterogeneity (I<sup>2</sup> ≥ 97%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Considerable heterogeneity (I<sup>2</sup> = 88%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>11</sup> Small sample size.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>12</sup> Methodological heterogeneity (downgraded two levels in
combination with inconsistency and precision).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>13</sup> Low event rate, confidence interval for the risk
difference crosses the null (-8.5 to 2.7).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>14</sup> Two studies, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>15</sup> Low event rate.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>16</sup> Wide 95% prediction interval (-21.4% to 11.5%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>17</sup> Based on examination of relative effects.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>18</sup> Discrepant risk differences in the 3 trials.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>19</sup> Only 2 events in the 5 trials.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>20</sup> Potential confounding related to use of anti-emetics; 5
studies reported administering antiemtics prophylatically (some concerns
CINeMA).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>21</sup> Asymmetry of comparison-adjusted funnel plot.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>22</sup> Wide prediction interval.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>23</sup> Moderate heterogeneity (I<sup>2</sup> = 60%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>24</sup> Wide confidence interval consistent with thresholds
leading to different decisions. (Imprecision in combination with
inconsistency downgraded two levels.).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>25</sup> No heterogeneity (I<sup>2</sup> = 0%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>26</sup> Wide confidence interval consistent with thresholds
leading to different decisions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>27</sup> Low heterogeneity.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>28</sup> Confidence interval crossing the null.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>29</sup> Confidence interval crossing the null. Wide confidence
interval, low event rate.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>30</sup> Substantial heterogeneity (I<sup>2</sup> ≥ 71%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>31</sup> Confidence interval crossing the null. Exceedly low event
rate.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>32</sup> High heterogeneity, but to one small study.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>33</sup> Wide confidence interval.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>34</sup> Methodological heterogeneity (downgraded in combination
with inconsistency).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>35</sup> Methodological heterogeneity.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>36</sup> Variable results (not pooled).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>37</sup> Unclear on outcome assessor blinding in 2 studies and 1
study reported technical issues with device.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><a id="soeConfirm"></a></p>
<p><br/></p>
</div>
</div>
<div id="rating-systems-reference" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>Rating Systems Reference</strong><a
href="#rating-systems-reference" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
</div>
<div id="grade" class="section level1 hasAnchor">
<h1 class="hasAnchor">  GRADE<a href="#grade" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br> <font size = 4> <strong>High</strong> — We are very confident
that the true effect lies close to that of the estimate of the
effect.</p>
<p><strong>Moderate</strong> — We are moderately confident in the effect
estimate: The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially
different.</p>
<p><strong>Low</strong> — Our confidence in the effect estimate is
limited: The true effect may be substantially different from the
estimate of the effect.</p>
<p><strong>Very Low</strong> — We have very little confidence in the
effect estimate: The true effect is likely to be substantially different
from the estimate of effect.</p>
<p></font></p>
<div id="domains-downgrading" class="section level2 hasAnchor">
<h2 class="hasAnchor">Domains (downgrading)<a
href="#domains-downgrading" class="anchor-section"
aria-label="Anchor link to header"></a></h2>
<p><font size = 4></p>
<p><em>Bias</em> — Systematic error (eg, selection bias, confounding
bias, measurement bias).</p>
<p><em>Inconsistency</em> — Unexplained heterogeneity of results;
studies find effect estimates that differ widely.</p>
<p><em>Imprecision</em> — The range of plausible effects estimated from
relevant studies.</p>
<p><em>Indirectness</em> — Direct evidence consists of research that
directly compares the interventions which we are interested in,
delivered to the populations in which we are interested, and measures
the outcomes important to patients.</p>
<p><em>Other (eg, publication bias)</em> — Selective publication or
reporting of results (typically of positive results).</p>
</div>
<div id="domains-updgrading" class="section level2 hasAnchor">
<h2 class="hasAnchor">Domains (updgrading)<a href="#domains-updgrading"
class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><em>Effect Size</em></p>
<p><em>Dose-response</em></p>
<p><em>Plausible Residual Confounding</em></p>
<p></font></p>
<p><br/><br/></p>
</div>
</div>
<div id="accfaha" class="section level1 hasAnchor">
<h1 class="hasAnchor">  ACCF/AHA<a href="#accfaha"
class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p><font size = 4></p>
<p><strong>Level A</strong> — High-quality evidence from more than 1
RCTs. Meta-analyses of high-quality RCTs. One or more RCTs corroborated
by high-quality registry studies.</p>
<p><strong>Level B-R</strong> — Moderate-quality evidence from 1 or more
randomized controlled trials. Meta-analyses of moderate-quality
RCTs.</p>
<p><strong>Level B-NR</strong> — Moderate-quality evidence from 1 or
more well-designed, well-executed nonrandomized studies, observational
studies, or registry studies. Meta-analyses of such studies.</p>
<p><strong>Level C-LD</strong> — Randomized or nonrandomized
observational or registry studies with limitations of design or
execution. Meta-analyses of such studies. Physiological or mechanistic
studies in human subjects.</p>
<p><strong>Level C-EO</strong> — Consensus of expert opinion based on
clinical experience when evidence is insufficient, vague, or
conflicting.</p>
<p></font></p>
<p><font size = 3> RCT: randomized controlled trial; NR: nonrandomized;
LD: limited data; EO: expert opinion </font></p>
<p>  <br/></p>
<br>
<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-sessioninfo" data-toggle="collapse" data-target="#workflowr-sessioninfo" style="display: block;">
<span class="glyphicon glyphicon-wrench" aria-hidden="true"></span>
Session information
</button>
</p>
<div id="workflowr-sessioninfo" class="collapse">
<pre><code>R version 4.2.1 (2022-06-23)
Platform: x86_64-apple-darwin17.0 (64-bit)
Running under: macOS Big Sur ... 10.16

Matrix products: default
BLAS:   /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRblas.0.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRlapack.dylib

locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

attached base packages:
[1] stats     graphics  grDevices utils     datasets  methods   base     

other attached packages:
 [1] formattable_0.2.1 naniar_0.6.1      forcats_0.5.2     stringr_1.4.1    
 [5] dplyr_1.0.10      purrr_0.3.5       readr_2.1.3       tidyr_1.2.1      
 [9] tibble_3.1.8      ggplot2_3.3.6     tidyverse_1.3.2   Cairo_1.6-0      
[13] countrycode_1.4.0 janitor_2.1.0     kableExtra_1.3.4 

loaded via a namespace (and not attached):
 [1] httr_1.4.4          sass_0.4.2          jsonlite_1.8.2     
 [4] viridisLite_0.4.1   modelr_0.1.9        bslib_0.4.0        
 [7] assertthat_0.2.1    googlesheets4_1.0.1 cellranger_1.1.0   
[10] yaml_2.3.5          pillar_1.8.1        backports_1.4.1    
[13] visdat_0.5.3        glue_1.6.2          digest_0.6.29      
[16] promises_1.2.0.1    rvest_1.0.3         snakecase_0.11.0   
[19] colorspace_2.0-3    htmltools_0.5.3     httpuv_1.6.6       
[22] pkgconfig_2.0.3     broom_1.0.1         haven_2.5.1        
[25] scales_1.2.1        webshot_0.5.4       svglite_2.1.0      
[28] later_1.3.0         tzdb_0.3.0          git2r_0.30.1       
[31] googledrive_2.0.0   generics_0.1.3      ellipsis_0.3.2     
[34] cachem_1.0.6        withr_2.5.0         cli_3.4.1          
[37] magrittr_2.0.3      crayon_1.5.2        readxl_1.4.1       
[40] evaluate_0.17       fs_1.5.2            fansi_1.0.3        
[43] xml2_1.3.3          tools_4.2.1         hms_1.1.2          
[46] gargle_1.2.1        lifecycle_1.0.3     munsell_0.5.0      
[49] reprex_2.0.2        compiler_4.2.1      jquerylib_0.1.4    
[52] systemfonts_1.0.4   rlang_1.0.6         grid_4.2.1         
[55] rstudioapi_0.14     htmlwidgets_1.5.4   rmarkdown_2.17     
[58] gtable_0.3.1        rematch_1.0.1       DBI_1.1.3          
[61] R6_2.5.1            lubridate_1.8.0     knitr_1.40         
[64] fastmap_1.1.0       utf8_1.2.2          workflowr_1.7.0    
[67] rprojroot_2.0.3     stringi_1.7.8       Rcpp_1.0.9         
[70] vctrs_0.4.2         dbplyr_2.2.1        tidyselect_1.2.0   
[73] xfun_0.33          </code></pre>
</div>
</div>


<!-- Adjust MathJax settings so that all math formulae are shown using
TeX fonts only; see
https://docs.mathjax.org/en/latest/web/configuration.html. This will make
the presentation more consistent at the cost of the webpage sometimes
taking slightly longer to load. Note that this only works because the
footer is added to webpages before the MathJax javascript. -->
<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    "HTML-CSS": { availableFonts: ["TeX"] }
  });
</script>




</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
